0001415889-24-010514.txt : 20240408 0001415889-24-010514.hdr.sgml : 20240408 20240408172224 ACCESSION NUMBER: 0001415889-24-010514 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240404 FILED AS OF DATE: 20240408 DATE AS OF CHANGE: 20240408 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Patel Sanj K CENTRAL INDEX KEY: 0001532218 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38492 FILM NUMBER: 24830512 MAIL ADDRESS: STREET 1: C/O KINIKSA PHARMACEUTICALS, LTD. STREET 2: CLARENDON HOUSE, 2 CHURCH STREET CITY: HAMILTON STATE: D0 ZIP: HM11 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Kiniksa Pharmaceuticals, Ltd. CENTRAL INDEX KEY: 0001730430 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: D0 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: CLARENDON HOUSE STREET 2: 2 CHURCH STREET CITY: HAMILTON STATE: D0 ZIP: HM11 BUSINESS PHONE: 7814399100 MAIL ADDRESS: STREET 1: CLARENDON HOUSE STREET 2: 2 CHURCH STREET CITY: HAMILTON STATE: D0 ZIP: HM11 4 1 form4-04082024_090415.xml X0508 4 2024-04-04 0001730430 Kiniksa Pharmaceuticals, Ltd. KNSA 0001532218 Patel Sanj K C/O KINIKSA PHARMACEUTICALS, LTD. CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM 11 BERMUDA true true false false CHAIRMAN & CEO 0 Class A Common Share 2024-04-08 4 M 0 9992 A 67087 D Class A Common Share 2024-04-08 4 F 0 4075 17.90 D 63012 D Class A Common Share 109795 I Held by The Marina 2016 Irrevocable Trust, u/d/t June 23, 2016 Share Option 18.06 2024-04-04 4 A 0 129750 0 A 2034-03-31 Class A Common Share 129750 129750 D Performance Share Unit 2024-04-04 4 A 0 20000 0 A 2034-03-31 Class A Common Share 20000 20000 D Restricted Share Unit 2024-04-04 4 A 0 24950 0 A Class A Common Share 24950 44393 D Restricted Share Unit 2024-04-08 4 M 0 9992 0 D Class A Common Share 9992 34401 D Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal month installments thereafter. The vesting commencement date is April 1, 2024. Each Performance Share Unit (PSU) represents a contingent right to receive a number of Class A Common Shares of the Issuer based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee. Unless earlier forfeited, each PSU vests and converts into not more than 200% of one Class A Common Share of the Issuer no later than January 30, 2027, unless such date falls on a non-business date, in which case the next business date shall apply. The RSUs vest over a four year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2024, and each yearly anniversary thereafter. The RSUs vest over a four-year period, with 25% of the RSs vesting on the yearly anniversary of the grant date, April 7, 2022. /s/ Madelyn Zeylikman, Attorney-in-Fact 2024-04-08